	US 12,448,421 B2
	Non-transgene transfection for therapeutic purposes
Mark C. Herzberg, Minneapolis, MN (US); Karen Farnie Ross, St. Paul, MN (US); and Brent S. Sorenson, Maplewood, MN (US)
Assigned to Antibiotic Alternatives LLC, Minneapolis, MN (US)
Filed by Antibiotic Alternatives LLC, Minneapolis, MN (US)
Filed on Jan. 30, 2024, as Appl. No. 18/427,711.
Application 18/427,711 is a division of application No. 16/842,489, filed on Apr. 7, 2020, granted, now 11,912,744.
Application 16/842,489 is a division of application No. 14/760,077, abandoned, previously published as PCT/US2014/011041, filed on Jan. 10, 2014.
Claims priority of provisional application 61/751,504, filed on Jan. 11, 2013.
Prior Publication US 2024/0166701 A1, May 23, 2024
Int. Cl. A61K 48/00 (2006.01); A61K 31/7105 (2006.01); C07K 14/47 (2006.01); C12N 15/12 (2006.01); C12N 15/52 (2006.01); C12N 15/87 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 48/00 (2013.01); A61K 48/005 (2013.01); C12N 15/87 (2013.01); C12N 2840/203 (2013.01)]

16 Claims

1. A method of suppressing squamous epithelial carcinoma cell hyperproliferation in a subject comprising:

topically applying to a squamous epithelial carcinoma cell that is S100A8 and S100A9 negative in the subject a composition comprising:

(i) at least one in vitro transcribed isolated mRNA that encodes at least two polypeptides involved in suppressing cell proliferation, wherein the at least two polypeptides comprise S100A8 and S100A9, and

(ii) a pharmaceutically acceptable in vivo delivery vehicle formulated for topical application, whereby the at least one in vitro transcribed isolated mRNA transfected in vivo expresses the at least two polypeptides in the squamous epithelial carcinoma cell in the subject to suppress hyperproliferation of the squamous epithelial carcinoma cell, wherein the squamous epithelial carcinoma cell is selected from the group consisting of a head and neck cancer, an orthotopic cancer, and an esophageal cancer.